Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual Pi3k/Mtor Inhibitors Pf-04691502 And Pf-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer

NCT01347866 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01347866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01347866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual Pi3k/Mtor Inhibitors Pf-04691502 And Pf-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2011
Completion date
December 31, 2015
Enrollment
105 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer